These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28869359)

  • 1. Monitoring of hemostatic abnormalities in major orthopedic surgery patients treated with edoxaban by APTT waveform.
    Hasegawa M; Wada H; Tone S; Yamaguchi T; Wakabayashi H; Ikejiri M; Watanabe M; Fujimoto N; Matsumoto T; Ohishi K; Yamashita Y; Katayama N; Sudo A
    Int J Lab Hematol; 2018 Feb; 40(1):49-55. PubMed ID: 28869359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
    AlHajri L; Jabbari S; AlEmad H; AlMahri K; AlMahri M; AlKitbi N
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):230-238. PubMed ID: 27811198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Edoxaban is effective in reducing the incidence of asymptomatic phlebographic events following closed-wedge high tibial osteotomy.
    Kobayashi H; Akamatsu Y; Kumagai K; Kusayama Y; Okuyama H; Hirotomi K; Shinohara K; Saito T
    Orthop Traumatol Surg Res; 2017 Dec; 103(8):1193-1196. PubMed ID: 28928048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
    Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
    Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Evaluation of Hemostatic Abnormalities Using a CWA-Small Amount Tissue Factor Induced FIX Activation Assay in Major Orthopedic Surgery Patients.
    Hasegawa M; Tone S; Wada H; Naito Y; Matsumoto T; Yamashita Y; Shimaoka M; Sudo A
    Clin Appl Thromb Hemost; 2021; 27():10760296211012094. PubMed ID: 34027710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform.
    Katayama H; Matsumoto T; Wada H; Fujimoto N; Toyoda J; Abe Y; Ohishi K; Yamashita Y; Ikejiri M; Habe K; Katayama N
    Clin Appl Thromb Hemost; 2018 Oct; 24(7):1170-1176. PubMed ID: 29439640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2015; 13(7):811-24. PubMed ID: 26068539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
    Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery.
    Kuroda Y; Hirayama C; Hotoda H; Nishikawa Y; Nishiwaki A
    Vasc Health Risk Manag; 2013; 9():593-8. PubMed ID: 24124376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Hurst KV; O'Callaghan JM; Handa A
    Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
    Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
    Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
    Cuker A; Husseinzadeh H
    J Thromb Thrombolysis; 2015 Apr; 39(3):288-94. PubMed ID: 25669624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
    Rohatagi S; Mendell J; Kastrissios H; Green M; Shi M; Patel I; Salazar DE
    Thromb Haemost; 2012 Nov; 108(5):887-95. PubMed ID: 23014669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
    Sprynger M
    Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
    Morishima Y; Kamisato C; Honda Y
    Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
    Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T
    Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.